Codexis, Inc. (CDXS) Bundle
Understanding Codexis, Inc. (CDXS) Revenue Streams
Understanding Codexis, Inc.’s Revenue Streams
The revenue for Codexis, Inc. is derived from three primary sources: product revenue, research and development revenue, and royalties and license revenue.
Breakdown of Primary Revenue Sources
| Revenue Source | Q3 2024 (in thousands) | Q3 2023 (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|
| Product Revenue | $11,158 | $5,395 | $5,763 | 107% |
| Research and Development Revenue | $1,675 | $3,882 | $(2,207) | (57%) |
| Total Revenue | $12,833 | $9,277 | $3,556 | 38% |
In the nine months ended September 30, 2024, the revenue sources were as follows:
| Revenue Source | 9M 2024 (in thousands) | 9M 2023 (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|
| Product Revenue | $26,968 | $24,807 | $2,161 | 9% |
| Research and Development Revenue | $10,917 | $18,775 | $(7,858) | (42%) |
| Total Revenue | $37,885 | $43,582 | $(5,697) | (13%) |
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate indicates a significant increase in product revenue in Q3 2024 compared to Q3 2023, with a growth of 107%. However, research and development revenue saw a decline of (57%) during the same quarter. In the nine-month period, total revenues decreased by (13%) primarily due to lower research and development revenue.
Contribution of Different Business Segments to Overall Revenue
For Q3 2024, product revenue contributed approximately 87% of total revenue, while research and development revenue accounted for about 13%. In the nine months ended September 30, 2024, the contributions were 71% from product revenue and 29% from research and development revenue.
Analysis of Significant Changes in Revenue Streams
The substantial increase in product revenue in Q3 2024 is attributed to higher sales of biocatalysts and pharmaceutical intermediates. Conversely, the decline in research and development revenue was mainly due to reduced fees from collaborations and the absence of prior non-cash revenue recognized in 2023. The impact of these changes is evident in the overall revenue trend, which reflects the company's reliance on product sales for growth.
A Deep Dive into Codexis, Inc. (CDXS) Profitability
A Deep Dive into Codexis, Inc.'s Profitability
Gross Profit, Operating Profit, and Net Profit Margins
| Metric | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Change | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 | Change |
|---|---|---|---|---|---|---|
| Total Revenue | $12,833,000 | $9,277,000 | +38% | $37,885,000 | $43,582,000 | -13% |
| Cost of Revenue | $4,317,000 | $2,249,000 | +92% | $12,634,000 | $9,947,000 | +27% |
| Gross Profit | $8,516,000 | $7,028,000 | +21% | $25,251,000 | $33,635,000 | -25% |
| Operating Loss | ($16,557,000) | ($32,060,000) | +48% | ($51,178,000) | ($68,350,000) | +25% |
| Net Loss | ($20,640,000) | ($34,908,000) | +41% | ($54,900,000) | ($69,048,000) | +20% |
Trends in Profitability Over Time
In the three months ended September 30, 2024, the company reported a gross profit margin of 66.4% compared to 75.8% in the same period of the previous year. For the nine months ended September 30, 2024, the gross profit margin was 66.6%, down from 77.2% in 2023.
Comparison of Profitability Ratios with Industry Averages
The industry average gross margin for biotechnology companies is approximately 70%. Codexis, Inc.'s gross margin of 66.4% for Q3 2024 falls slightly below the industry average.
Analysis of Operational Efficiency
- Research and Development Expenses: $11,505,000 (Q3 2024) vs. $13,662,000 (Q3 2023)
- Selling, General and Administrative Expenses: $13,568,000 (Q3 2024) vs. $12,302,000 (Q3 2023)
- Decrease in R&D expenses of 16% year-over-year, while SG&A increased by 10%.
- Overall operational efficiency improved, with a 48% reduction in operating loss year-over-year.
Cost Management and Gross Margin Trends
| Cost Category | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Change |
|---|---|---|---|
| Cost of Product Revenue | $4,317,000 | $2,249,000 | +92% |
| Research and Development | $11,505,000 | $13,662,000 | -16% |
| Selling, General and Administrative | $13,568,000 | $12,302,000 | +10% |
For the nine months ended September 30, 2024, total costs and operating expenses were $89,063,000, a decrease of 20% compared to $111,932,000 in the same period of 2023.
Debt vs. Equity: How Codexis, Inc. (CDXS) Finances Its Growth
Debt vs. Equity: How Codexis, Inc. Finances Its Growth
The company has a total debt of $30.0 million under a term loan agreement with Innovatus Life Sciences Lending Fund I, LP, with a maturity date set for February 13, 2029. This loan allows for potential additional borrowing of up to $10.0 million upon achieving specific financial milestones.
As of September 30, 2024, the company's debt-to-equity ratio was calculated at 0.41, which is below the industry average of 0.5 for biotechnology firms, indicating a conservative approach to leveraging.
In terms of liquidity, as of September 30, 2024, the company had $37.5 million in cash and cash equivalents, alongside $52.8 million in short-term investments, resulting in a working capital balance of $77.8 million.
Recent Debt Issuances and Credit Ratings
In February 2024, the company secured a loan of $30.0 million from Innovatus, indicating a proactive move to strengthen its balance sheet amid ongoing operational costs. The credit rating for this debt has not been explicitly stated, but the terms suggest a favorable stance from lenders given the structured repayment plan and potential for additional borrowing.
Debt Financing vs. Equity Funding
The firm has historically utilized both debt and equity to finance its operations. In 2024, it raised $31.3 million through common stock issuance under an equity sales agreement. This approach helps to dilute equity less than traditional methods while providing necessary capital for growth initiatives.
The following table summarizes the company's financial structure as of September 30, 2024:
| Financial Metric | Amount |
|---|---|
| Total Debt | $30.0 million |
| Debt-to-Equity Ratio | 0.41 |
| Cash and Cash Equivalents | $37.5 million |
| Short-term Investments | $52.8 million |
| Working Capital | $77.8 million |
| Equity Raised in 2024 | $31.3 million |
This strategic balance between debt and equity financing reflects the company's efforts to maintain financial stability while pursuing growth opportunities.
Assessing Codexis, Inc. (CDXS) Liquidity
Assessing Codexis, Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as follows:
| Current Assets | Current Liabilities | Current Ratio |
|---|---|---|
| $90,255,000 | $12,482,000 | 7.23 |
Quick Ratio: The quick ratio is determined using:
| Quick Assets | Current Liabilities | Quick Ratio |
|---|---|---|
| $90,255,000 | $12,482,000 | 7.23 |
Analysis of Working Capital Trends
Working capital as of September 30, 2024, was $77,773,000, compared to $57,636,000 as of December 31, 2023, indicating a significant increase in liquidity.
Cash Flow Statements Overview
The cash flow from operating activities for the nine months ended September 30, 2024, was $(32,942,000), compared to $(41,601,000) for the same period in 2023, showing an improvement in cash usage.
Cash flows from investing activities were $(54,117,000) for the nine months ended September 30, 2024, compared to $(5,962,000) in 2023.
Cash flows from financing activities amounted to $59,390,000 for the nine months ended September 30, 2024, up from $8,167,000 in 2023, primarily due to proceeds from the Innovatus Loan and equity sales.
| Cash Flow Activity | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Used in Operating Activities | $(32,942) | $(41,601) |
| Net Cash Used in Investing Activities | $(54,117) | $(5,962) |
| Net Cash Provided by Financing Activities | $59,390 | $8,167 |
Potential Liquidity Concerns or Strengths
Cash and cash equivalents as of September 30, 2024, were $37,452,000, down from $65,116,000 at the end of 2023. This decrease is attributed to cash used in investing activities.
Short-term investments have increased to $52,803,000 as of September 30, 2024, indicating a strategy to maintain liquidity while investing in growth opportunities.
The company has a loan agreement with Innovatus totaling $40,000,000, with $30,000,000 drawn down as of February 13, 2024, which provides additional liquidity support.
Is Codexis, Inc. (CDXS) Overvalued or Undervalued?
Valuation Analysis
To assess the valuation of Codexis, Inc. (CDXS), we will examine key financial ratios and stock performance metrics. This analysis will help determine whether the company is overvalued or undervalued based on current market conditions.
Price-to-Earnings (P/E) Ratio
The current P/E ratio for Codexis is not applicable due to the company's net loss in the most recent financial periods. For the nine months ended September 30, 2024, the net loss was $54.9 million, translating to a loss per share of $0.78.
Price-to-Book (P/B) Ratio
The company's book value per share as of September 30, 2024, is calculated as follows:
- Total stockholders' equity: $73.4 million
- Total shares outstanding: 81.376 million
- Book value per share: $0.90 (calculated as $73.4 million / 81.376 million shares)
The current market price of CDXS shares is approximately $1.50, leading to a P/B ratio of approximately 1.67 (calculated as $1.50 / $0.90).
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
As of September 30, 2024, Codexis reported an EBITDA of ($51.2 million) for the nine-month period. The enterprise value is calculated as follows:
- Market capitalization: $121.5 million (current stock price of $1.50 multiplied by shares outstanding)
- Total debt: $30.0 million (as per the Innovatus Loan)
- Cash and cash equivalents: $37.5 million
- Enterprise value: $113.5 million (calculated as market cap + total debt - cash)
The EV/EBITDA ratio is not applicable due to the negative EBITDA.
Stock Price Trends
Over the last 12 months, the stock price of Codexis has experienced significant volatility:
- 12-month high: $2.25
- 12-month low: $0.85
- Current stock price: $1.50
Dividend Yield and Payout Ratios
Codexis does not currently pay a dividend, hence the dividend yield is 0% and the payout ratio is not applicable.
Analyst Consensus on Stock Valuation
Analyst ratings for Codexis as of 2024 are as follows:
- Buy: 3
- Hold: 2
- Sell: 1
The consensus indicates a moderate buy recommendation based on the potential for recovery and growth in product revenue.
| Metric | Value |
|---|---|
| Net Loss (9M 2024) | $54.9 million |
| Loss per Share | $0.78 |
| Book Value per Share | $0.90 |
| P/B Ratio | 1.67 |
| Market Capitalization | $121.5 million |
| Total Debt | $30.0 million |
| Cash and Cash Equivalents | $37.5 million |
| Enterprise Value | $113.5 million |
| 12-Month High | $2.25 |
| 12-Month Low | $0.85 |
| Current Stock Price | $1.50 |
| Dividend Yield | 0% |
| Analyst Buy Ratings | 3 |
| Analyst Hold Ratings | 2 |
| Analyst Sell Ratings | 1 |
Key Risks Facing Codexis, Inc. (CDXS)
Key Risks Facing Codexis, Inc.
The financial health of Codexis, Inc. is influenced by various internal and external risk factors. Understanding these risks is essential for investors seeking to evaluate the company’s potential performance.
Overview of Risks
Codexis faces multiple risks that could impact its financial stability:
- Industry Competition: The biotechnology sector is highly competitive, with numerous companies vying for market share in enzyme technology. Increased competition could lead to pricing pressures and reduced market share.
- Regulatory Changes: The company operates under strict regulatory oversight which can change. New regulations may increase operational costs or limit market opportunities.
- Market Conditions: Fluctuations in market demand for biocatalysts and pharmaceuticals can significantly impact revenue streams.
Operational Risks
Recent earnings reports highlight several operational risks:
- Dependency on Third-Party Manufacturers: Codexis relies on third-party manufacturers for enzyme production. Any disruptions in their operations could adversely affect product availability.
- Revenue Volatility: Revenue from research and development can fluctuate, as seen with a 57% decrease in research and development revenue for the three months ended September 30, 2024, compared to the same period in 2023.
Financial Risks
Financial risks are also significant for Codexis:
- Net Losses: The company reported a net loss of $20.6 million for the three months ended September 30, 2024. This is an improvement from a net loss of $34.9 million in the same period in 2023, but ongoing losses raise concerns about sustainability.
- Debt Obligations: Codexis has a loan agreement with Innovatus, with an outstanding principal of $30 million as of September 30, 2024. The interest rates on this loan are subject to fluctuations, which can impact cash flow.
Strategic Risks
Strategic decisions can also pose risks:
- Restructuring Efforts: The recent restructuring aimed to streamline operations has led to a significant reduction in expenses. However, it may also affect the company's ability to innovate and expand.
- Key Customer Concentration: A significant portion of revenues is derived from a few customers. For example, one customer accounted for 18% of total revenues in Q3 2024.
Mitigation Strategies
Codexis has implemented several strategies to mitigate these risks:
- Diversification of Customer Base: Efforts are being made to reduce reliance on a limited number of customers by expanding the customer base and exploring new market opportunities.
- Cost Management Initiatives: The company is actively managing cash usage and optimizing operational costs to maintain sufficient liquidity.
Financial Metrics
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Loss | $20.6 million | $34.9 million | Improvement of $14.3 million |
| Research & Development Revenue | $1.675 million | $3.882 million | Decrease of $2.207 million |
| Cash and Cash Equivalents | $37.452 million | $65.116 million | Decrease of $27.664 million |
| Short-term Investments | $52.803 million | $0 | Increase of $52.803 million |
| Working Capital | $77.773 million | $57.636 million | Increase of $20.137 million |
Future Growth Prospects for Codexis, Inc. (CDXS)
Future Growth Prospects for Codexis, Inc. (CDXS)
Product Innovations: Codexis has focused on enhancing its product offerings, particularly in biocatalysts and enzyme technologies. The recent exclusive licensing agreement with Roche Sequencing Solutions, which includes the newly engineered double-stranded DNA ligase, is expected to bring in significant revenues. The agreement provided upfront and technical milestone payments, with $6.0 million recognized in research and development revenue during Q1 2024.
Market Expansions: The company is actively pursuing expansion within the biopharmaceutical sector. Product revenue saw a remarkable increase of 107% year-over-year in Q3 2024, amounting to $11.2 million compared to $5.4 million in Q3 2023. This growth is attributed to higher sales of branded pharmaceutical products.
Acquisitions: Codexis is strategically positioned to explore acquisitions that can bolster its R&D capabilities and enhance its market presence. The company’s collaboration with Pfizer has yielded substantial non-cash revenue, although R&D revenue decreased by 57% to $1.7 million in Q3 2024, down from $3.9 million in Q3 2023.
| Growth Driver | Details | Impact |
|---|---|---|
| Product Innovations | Exclusive licensing agreement with Roche for dsDNA ligase | Upfront payments and projected revenues of $6.0 million |
| Market Expansions | Increased sales in biopharmaceuticals | 107% growth in product revenue in Q3 2024 |
| Acquisitions | Potential for strategic acquisitions to enhance R&D | Increased collaborative opportunities and market share |
Future Revenue Growth Projections: Analysts project a compound annual growth rate (CAGR) of approximately 15% for biocatalysts through 2025, which positions Codexis favorably as it continues to innovate and expand.
Earnings Estimates: For the full year 2024, the company is expected to report revenues of approximately $50 million, driven by product sales and collaboration agreements. The net loss for the nine months ended September 30, 2024, was reported at $54.9 million, with a significant decrease from $69.0 million in the same period in 2023.
Strategic Initiatives and Partnerships: Codexis has entered into several key collaborations with major pharmaceutical companies, which are expected to enhance its growth trajectory. These partnerships not only provide immediate revenue streams but also position the company for future market opportunities.
Competitive Advantages: Codexis's proprietary technology platforms give it a competitive edge in enzyme engineering, allowing for quicker and more efficient product development. The company's strong intellectual property portfolio further solidifies its market position.
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Total Revenues | $12.8 million | $9.3 million | +38% |
| Net Loss | $20.6 million | $34.9 million | -41% |
| Product Revenue | $11.2 million | $5.4 million | +107% |
In summary, Codexis's ongoing product innovations, market expansions, and strategic partnerships position it well for future growth. The company's ability to leverage its competitive advantages and enhance its financial health will be crucial for attracting investor interest in the coming years.
Codexis, Inc. (CDXS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Codexis, Inc. (CDXS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Codexis, Inc. (CDXS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Codexis, Inc. (CDXS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.